Menu

Blog

Apr 23, 2020

Antimalarials widely used against COVID-19 heighten risk of cardiac arrest. How can doctors minimize the danger?

Posted by in category: biotech/medical

Treating COVID-19 patents with hydroxychloroquine, a derivative of chloroquine generally thought to have less severe side effects, has become standard at many hospitals. The drug is often combined with the antibiotic azithromycin, which some studies suggest also has antiviral effects. The U.S. Food and Drug Administration has authorized emergency use of both chloroquine and hydroxychloroquine for COVID-19 patients. But no large, randomized trial has proved these drugs—alone or in combination with azithromycin—are effective against the disease.

Cardiologists urge careful monitoring of patients on chloroquine or hydroxychloroquine.

Leave a reply